Slides on Key Decisions in HIV Care: What to Do About Missed CAB Plus RPV LA Injections?

Learn how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Format: Microsoft PowerPoint (.ppt)
File Size: 439 KB
Released: October 4, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Dr Milosz Parczewski discusses HIV Glasgow 2022 reports on the impact of the war in Ukraine on HIV care in Eastern Europe, from Clinical Care Options (CCO)

Milosz Parczewski, MD, PhD Released: November 22, 2022

Prof Don Smith discusses new HIV data from IDWeek 2022 on long-acting cabotegravir plus rilpivirine in this commentary from Clinical Care Options (CCO)

Don Smith, MD Released: November 22, 2022

Expert discussion of HIV Glasgow 2022 data on optimizing islatravir dosing based on lymphocyte changes and IDWeek 2022 data on LA CAB + RPV real-world effectiveness in the US OPERA Cohort, from Clinical Care Options (CCO)

Brenda E. Crabtree Ramírez, MD Released: November 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings